sector medic suppli devic
messag bryan hanson first call zimmer ceo downbeat
anticip emphasi risk opportun sugarco fact
compani face long road back struggl past year despit
came away call encourag mr hanson overal messag
increas convict zimmer right track rais price target
turnaround may take longer envis month ago
continu view zimmer attract play value-ori investor
year hamper suppli constraint return busi usual
take time surprisingli mr hanson identifi success resolut qualiti
suppli issu impact warsaw north facil first prioriti howev
character timelin process risk opportun
point importantli push compani prior target return
full suppli base convers manag sens zimmer
track remedi strategi laid call howev mr hanson
note project complex almost never go entir accord plan mani
key mileston remain chief among fda re-inspect facil also
sought temper expect quickli revenu growth could ramp suppli
normal note compani sale rep surgeon like
cautiou initi given length time zimmer impair numer
misstep along way
net set transit year zimmer provid
guidanc tuesday expect street number reset
reflect essenti earn growth second consecut year organ
revenu gain top-lin growth improv cours year
bottom quickli happen magnitud reacceler
remain open question manag note tuesday like
sever import new product set launch later year posit
move needl meaning way beyond still sluggish top line earn
also depress headwind lower bonu comp
desir part mr hanson ramp invest describ sever
year zimmer chase earn tri off-set revenu shortfal
despit somewhat gloomi near-term backdrop still see path stock
work said believ investor percept zimmer
becom year bigger determin near-term stock perform
quarterli result tuesday call reinforc view mr hanson right execut
lead turnaround next step articul vision actual
entail resolv situat warsaw north could open signific opportun
zimmer ww recon busi under-perform broader market due
larg part suppli constraint meanwhil compani ebita margin
narrow increas product cost lower overhead
absorpt crimp profit remedi cost
exclud adjust ep cash expens total work
complet larg chunk capit avail product use
recon busi back feet continu see opportun zimmer
augment long-term growth trajectori rethink portfolio sens
someth manag team alreadi spent fair amount time think
start prior mr hanson hire zimmer probabl still year away
balanc sheet flexibl aggress front action could come
sooner exist busi deem non-cor continu page
page analyst certif import disclosur
share still trade meaning discount large-cap med-tech
averag continu see risk/reward favor model call
adjust ep total revenu cc compar
prior estim respect current level zimmer
trade ntm ep forecast discount group averag
view discount warrant base compani inferior growth outlook
believ gap shrink growth reacceler manag articul
long-term plan creat sharehold valu rais price target
revis forward ntm ep forecast take account recent peer
group multipl expans signific upsid potenti target current level
reiter buy rate
page analyst certif import disclosur
zimmer merger biomet made player hip knee wide
margin share global recon sale deal provid compani
ep accret scale also left zimmer sale come slow growth
market underperform late under-perform
exacerb past year chronic manufactur issu suppli constraint
leav zimmer unabl servic client base effect remedi
issu taken far longer manag origin anticip believ
compani posit return normal inventori level drive
improv top-lin growth profit longer term continu see
opportun addit valu creation commit shed non-cor
asset diversifi higher growth adjac think strateg shift
would view posit street result higher multipl stock
today trade signific discount rest large-cap med-tech group
zimmer share current trade ntm ep estim ntm
ebitda well large-cap med-tech averag view
discount broader group justifi given zimmer inferior top-lin growth
trajectori vs see current valuat gap excess expect
share re-rat upward market discount possibl new
manag drive growth reacceler rais price target
base multipl revis forward
ntm ep estim signific upsid potenti target current level
assign zimmer share buy rate
downsid risk rate includ failur attract talent new leadership and/or
implement strateg shift drive sustain valu creation increas price and/or
volum pressur ortho implant manufactur bundl payment initi
greater anticip share loss recon due linger suppli constraint
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
figur annual revenu build pro forma bmet deal jan
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
